Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of antibiotics: participants experiencing cough · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
It is very uncertain whether inhaled tobramycin (TNS) changes adverse effects of antibiotics: participants experiencing cough compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · neonates with sepsis
Pentoxifylline with antibiotics (any dose or duration) may leads to lower all‐cause mortality during hospital stay compared with placebo or no intervention (low certainty).
1 finding from 1 review
Chronic lung disease · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes chronic lung disease compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes severe intraventricular haemorrhage compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Periventricular leukomalacia · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes periventricular leukomalacia compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Length of hospital stay · neonates with sepsis
Pentoxifylline with antibiotics (any dose or duration) showed no clear difference in length of hospital stay (LOS) in days compared with placebo or no intervention (low certainty).
1 finding from 1 review
Necrotising enterocolitis · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes necrotising enterocolitis, any Bell stage compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Retinopathy of prematurity · neonates with sepsis
It is very uncertain whether pentoxifylline with antibiotics (any dose or duration) changes retinopathy of prematurity, any stage compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
1 finding from 1 review
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
Secondary hemorrhage at any time point · people with traumatic hyphema
Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: systemic hypotension · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found